# Pan-Canadian Pharmaceutical Alliance: No PCPA Negotiations

**As of September 30, 2014**

There are 16 drug products for which the PCPA has decided **not to negotiate** collectively or individually at the provincial-territorial level:

| Drug Product<br>Brand Name (Generic Name) | Indication/Use |
|---|---|
| **Afinitor (everolimus)** | Used to treat renal angiomyolipoma |
| **Apprilon (doxycycline)** | Used to treat inflammatory rosacea |
| **Benlysta (belimumab)** | Used to treat lupus |
| **Bystolic (nebivolol)** | Used to treat hypertension |
| **Edarbi (azilsartan)** | Used to treat high blood pressure |
| **Edarbyclor (azilsartan/chlorthalidone)** | Used to treat high blood pressure |
| **Erbitux (cetuximab)** | Used in combination with FOLFIRI for first-line treatment of KRAS wild type metastatic colorectal cancer |
| **Fampyra (fampiridine)** | Used to treat Multiple Sclerosis |
| **Neupro (rotigotine)** | Used to treat idiopathic Parkinson disease |
| **Samsca (tolvaptan)** | Used to treat hyponatremia |
| **Soliris (eculizumab)** | Used to treat aHUS |
| **Stivarga (regorafenib)** | Used to treat metastatic colorectal cancer |
| **Sublinox (zolpidem)** | Used to treat acute insomnia |
| **Tykerb (lapatinib)** | Used in combination with letrozole to treat metastatic breast cancer |
| **Xiaflex (collagenase clostridium histolyticum)** | Used to treat Dupuytren's contracture |
| **Zaltrap (aflibercept)*** | Used to treat metastatic colorectal cancer |

*One new drug product since last update of August 31, 2014.

Each drug product is considered individually based on a number of factors, including the recommendation from the Canadian Drug Expert Committee (CDEC) or the pan-Canadian Oncology Drug Review Expert Review Committee (pERC), patient perspective, clinical need and considerations. The majority of products for which the PCPA and the provinces and territories do not pursue negotiations have received negative recommendations from CDEC or pERC due to clinical concerns, such as uncertainty regarding the clinical benefit of the drug product. If new information becomes available to address the concerns raised by PCPA and the applicable national review committee, the PCPA may reconsider their decision.

Note: Since the update of July 31, 2014, one drug product has been removed from the list above:

- Esbriet (pirfenidone) received a final CDEC recommendation not to list on April 18, 2013. An arrangement between jurisdictions and the manufacturer has been reached to provide patient access on an interim basis until a new CDEC recommendation has been made.

Note: Since the update of February 28, 2014, two drug products have been removed from the list above:

- Latuda (lurasidone) received a new CDEC recommendation based on a resubmission from the manufacturer. PCPA reconsidered their decision and recommended that negotiations for this product be considered by each Province/Territory individually.
- Lodalis (colesevelam) received a final CDEC recommendation not to list at the resubmitted price on December 19, 2012. The manufacturer submitted a proposal to the PCPA leading to the PCPA's decision to engage in joint negotiations on this product.

***Note:*** *Nunavut is not participating in the Pan-Canadian Pharmaceutical Alliance*

**www.canadaspremiers.ca**